Targovax ASA

Cell and Gene Therapy, Industrial Impact

GenScript | March 03, 2023

GenScript Biotech Corporation, a leading tools and services provider for life-science research, recently announced the expansion of its Singapore facility to provide a high-quality gene synthesis service. This expansion has added 976 square meters to the facility, bringing its total size to 3,500 square meters, making it the third-largest facility for GenScript globally. This development will also increase the staff at the Singapore facility to 150. In February 2022, GenScript A...

Industrial Impact

Aanika Biosciences, | February 25, 2022

Aanika Biosciences, an emerging biotech company using microbial based technologies to protect the safety and security of our food system, announced today it has received acceptance into the Bermuda Monetary Authority’s (BMA) Innovation Hub. The program will allow reinsurers to explore how the application of Aanika’s traceability and prevention technology can help reduce the magnitude and size of claims while lowering premiums and expanding protection for the food and agriculture indu...

FierceBiotech | January 21, 2020

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline. After seeming to turn away from oncology R&D under its old CEO Sir Andrew Witty a few years ago, new CEO and R&D head Emma Walmsley and Hal Barron, respectively, have made powering their pipeline out of the slow lane the priority. Today, GSK announced that one of its top prospects (and a drug Barron has singled out in the past) has been handed an FD...

Industrial Impact

PDS Biotechnology | October 04, 2022

PDS Biotechnology Corporation a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® for the treatment of unresectable, recurrent/metastatic human papilloma virus 16-positive head and neck squamous cell carcinoma. Read More